Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer 

Database studies in this rare cancer suggest that chemotherapy may provide survival benefit in node-positive tumours and that the KRAS G12D mutation could be a potential therapeutic target 

Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments 

CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies  

Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors 

Pre-treatment expression of Ki-67 plus FOXC1 plus PD-L1 predicted response to neoadjuvant treatment in breast and head and neck tumours, although more work is required to determine its use in the context of immunotherapy alone 

A joint analysis of the OnCovid and ESMO-CoCARE registries confirms the protective role of anti-SARS-CoV-2 vaccination in cancer patients treated with immunotherapy 

Phase II study indicates that SHR-1701 alone or together with chemotherapy may be a valuable induction strategy in stage III unresectable NSCLC 

However, improved outcomes are reported in PD-L1-positive patients only irrespective of post-operative and post-chemotherapy ctDNA status, calling into question its predictive value

Positive results from a phase II trial adds weight to the value of immunotherapy as neoadjuvant treatment for resectable NSCLC